Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Rhea-AI Summary

Absci (Nasdaq: ABSI) priced an underwritten public offering of 13,495,277 common shares at $7.41 per share, for expected gross proceeds of about $100 million.

According to Absci, funds will advance ABS-201 for androgenetic alopecia and endometriosis and support general corporate purposes, with closing expected June 25, 2026.

Positive

• Approximately $100 million in expected gross proceeds from the underwritten equity offering
• Pricing of 13,495,277 shares at $7.41 per share provides fresh primary capital
• Proceeds earmarked to advance ABS-201 in androgenetic alopecia and endometriosis
• Participation from Eli Lilly & Company and multiple leading institutional investors
• All offered shares are sold by Absci, directing proceeds to the company rather than selling shareholders

Negative

• Issuance of 13,495,277 new shares at $7.41 implies equity dilution for existing shareholders

News Market Reaction – ABSI

+35.96% 5.4x vol

53 alerts

+35.96% Session close to close

+45.0% Peak in 27 hr

$1.75B Market Cap

5.4x Rel. Volume

In the Jun 24 session, ABSI gained 35.96%, reflecting a significant positive market reaction. Argus tracked a peak move of +45.0% during that session. Our momentum scanner triggered 53 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 5.4x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +36.0% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +36.0% in the session following this news. A strong positive reaction aligns with prior enthusiasm around ABS-201 and AI-designed therapeutics, but the new equity adds dilution. Elevated short interest and sizable remaining shelf capacity could still introduce sharp reversals if sentiment weakens.

Key Figures

Offering size: $100 million Shares offered: 13,495,277 shares Offering price: $7.41 per share +5 more

8 metrics

Offering size $100 million Gross proceeds from underwritten common stock offering

Shares offered 13,495,277 shares Common stock to be sold by Absci in the offering

Offering price $7.41 per share Public offering price before underwriting discounts

Expected close date June 25, 2026 Planned closing of the underwritten offering

Form S-3 file number 333-289541 Shelf registration statement used for this offering

Shelf filing date August 12, 2025 Date Form S-3 shelf was filed with SEC

Shelf effective date August 22, 2025 Date Form S-3 shelf registration became effective

Shelf capacity $400,000,000 Maximum aggregate offering amount under S-3 shelf

Previous Offering Reports

2 past events · Latest: Jul 24 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 24	Stock offering priced	Negative	-17.7%	Public offering of 16,670,000 shares at $3.00 to raise $50M gross.
Jul 24	Offering proposed	Negative	-17.7%	Proposed $50M common stock sale with $7.5M overallotment option.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ABSI has historically traded lower on equity offering announcements, showing a consistent negative reaction to dilution events.

Key Terms

underwritten offering, shelf registration statement, form s-3, androgenetic alopecia, +2 more

6 terms

underwritten offering financial

"today announced the pricing of an underwritten offering of 13,495,277 shares"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

shelf registration statement regulatory

"offered by Absci pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3 (File No. 333-289541)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

androgenetic alopecia medical

"advancement of ABS-201™ across androgenetic alopecia and endometriosis"

Androgenetic alopecia is a common form of hair loss characterized by gradual thinning and receding of hair, often following a predictable pattern. It results from a combination of genetic factors and hormone influences, similar to how certain plants are more susceptible to environmental stress. For investors, understanding trends in health and wellness, including conditions like this, can highlight shifts in consumer demand for related products and treatments.

endometriosis medical

"advancement of ABS-201™ across androgenetic alopecia and endometriosis"

Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility problems. It can impact a person's health and quality of life, potentially leading to increased healthcare costs and affecting workforce productivity. For investors, understanding conditions like endometriosis highlights the importance of healthcare innovations and markets related to women's health.

generative ai technical

"advancing breakthrough therapeutics designed with generative AI, today announced"

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci

Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis

VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten offering of 13,495,277 shares of its common stock at a price of $7.41 per share, before deducting underwriting discounts and commissions.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $100 million. All of the shares in the offering are to be sold by Absci.

Absci intends to use the net proceeds from the offering to fund the advancement of ABS-201, Absci’s AI-designed anti-PRLR antibody program across androgenetic alopecia (pattern hair loss) and endometriosis, and for working capital and other general corporate purposes.

Jefferies, J.P. Morgan, TD Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering. The offering is expected to close on or about June 25, 2026, subject to the satisfaction of customary closing conditions. The financing includes participation from Eli Lilly & Company alongside leading financial institutions including Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and a large investment management firm.

The shares of common stock are being offered by Absci pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289541) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on August 12, 2025 and became effective on August 22, 2025. The prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at prospectus_department@jefferies.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297-2926, or by email at TD.ECM_Prospectus@tdsecurities.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, express or implied statements regarding any or all of the following: market conditions and the satisfaction of customary closing conditions related to the offering and the intended use of proceeds from the offering, among others. Risks that contribute to the uncertain nature of the express or implied forward-looking statements in this press release include, without limitation, the risks and uncertainties inherent in biopharmaceutical development, including initiating, enrolling and conducting clinical trials; obtaining regulatory approval; protecting intellectual property; raising sufficient capital to support such efforts; and the risk that the costs to support such efforts may be higher than anticipated; as well as those risks and uncertainties discussed under the heading “Risk Factors” in Absci’s most recent quarterly report on Form 10-Q and in any other subsequent filings made by Absci with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Absci disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com

Media Contact
press@absci.com

FAQ

What did Absci (NASDAQ: ABSI) announce about its $100 million stock offering on June 24, 2026?

Absci announced pricing of an underwritten offering raising about $100 million in gross proceeds. According to Absci, the company is selling 13,495,277 common shares at $7.41 per share, with closing expected on or about June 25, 2026, subject to customary conditions.

How many shares is Absci (ABSI) issuing and at what price in its June 2026 offering?

Absci is issuing 13,495,277 common shares at an offering price of $7.41 per share. According to Absci, all shares are being sold by the company, and the transaction is expected to generate approximately $100 million in gross proceeds before fees and expenses.

How will Absci use the proceeds from its $100 million ABSI stock offering?

Absci plans to use the net proceeds to fund advancement of ABS-201 and for general purposes. According to Absci, the cash will support its AI-designed anti-PRLR antibody program for androgenetic alopecia and endometriosis, along with working capital and other corporate needs.

Which major investors are participating in Absci’s June 2026 ABSI equity financing?

The financing includes participation from Eli Lilly & Company and several large institutional investors. According to Absci, investors include Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and a large investment management firm, signaling interest from both strategic and financial backers.

Who are the joint book-running managers for Absci’s June 2026 ABSI stock offering?

The joint book-running managers are Jefferies, J.P. Morgan, TD Cowen, and Guggenheim Securities. According to Absci, these firms are managing the underwritten offering, which is being conducted under an effective shelf registration statement filed with and declared effective by the SEC.

What does the June 2026 Absci (ABSI) stock offering mean for existing shareholders?

The offering provides Absci with about $100 million in new capital but increases share count. According to Absci, proceeds will fund ABS-201 and operations; however, issuing 13,495,277 new shares at $7.41 per share implies dilution for current shareholders’ ownership percentages.